Iowa State Bank Decreases Stock Holdings in Pfizer Inc. $PFE

Iowa State Bank reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 93,654 shares of the biopharmaceutical company’s stock after selling 1,602 shares during the quarter. Iowa State Bank’s holdings in Pfizer were worth $2,270,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Relyea Zuckerberg Hanson LLC lifted its stake in shares of Pfizer by 40.2% during the 2nd quarter. Relyea Zuckerberg Hanson LLC now owns 13,331 shares of the biopharmaceutical company’s stock worth $323,000 after purchasing an additional 3,825 shares during the last quarter. Investors Asset Management of Georgia Inc. GA ADV lifted its stake in shares of Pfizer by 0.7% during the 2nd quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 95,272 shares of the biopharmaceutical company’s stock worth $2,309,000 after purchasing an additional 664 shares during the last quarter. Confluence Wealth Services Inc. lifted its stake in shares of Pfizer by 4.6% during the 2nd quarter. Confluence Wealth Services Inc. now owns 83,559 shares of the biopharmaceutical company’s stock worth $2,025,000 after purchasing an additional 3,638 shares during the last quarter. Cullinan Associates Inc. lifted its stake in shares of Pfizer by 18.3% during the 2nd quarter. Cullinan Associates Inc. now owns 76,501 shares of the biopharmaceutical company’s stock worth $1,854,000 after purchasing an additional 11,847 shares during the last quarter. Finally, Grimes & Company Inc. lifted its stake in shares of Pfizer by 2.2% during the 2nd quarter. Grimes & Company Inc. now owns 97,772 shares of the biopharmaceutical company’s stock worth $2,370,000 after purchasing an additional 2,089 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on PFE. UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday. Bank of America increased their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday. Morgan Stanley increased their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $28.41.

Pfizer Stock Up 1.1%

Shares of PFE stock opened at $27.37 on Monday. The stock’s 50-day simple moving average is $24.67 and its 200-day simple moving average is $24.12. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market capitalization of $155.59 billion, a PE ratio of 14.56, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.